Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Equity Ratio (2020 - 2023)

Historic Equity Ratio for Terns Pharmaceuticals (TERN) over the last 4 years, with Q3 2023 value amounting to 0.95.

  • Terns Pharmaceuticals' Equity Ratio fell 27.7% to 0.95 in Q3 2023 from the same period last year, while for Sep 2023 it was 0.95, marking a year-over-year decrease of 27.7%. This contributed to the annual value of 0.96 for FY2022, which is 116.21% up from last year.
  • According to the latest figures from Q3 2023, Terns Pharmaceuticals' Equity Ratio is 0.95, which was down 27.7% from 0.95 recorded in Q2 2023.
  • Terns Pharmaceuticals' Equity Ratio's 5-year high stood at 0.96 during Q4 2022, with a 5-year trough of 1.27 in Q4 2020.
  • Its 4-year average for Equity Ratio is 0.77, with a median of 0.95 in 2021.
  • As far as peak fluctuations go, Terns Pharmaceuticals' Equity Ratio skyrocketed by 17495.25% in 2021, and later tumbled by 179.0% in 2022.
  • Over the past 4 years, Terns Pharmaceuticals' Equity Ratio (Quarter) stood at 1.27 in 2020, then surged by 174.95% to 0.95 in 2021, then increased by 1.16% to 0.96 in 2022, then dropped by 1.42% to 0.95 in 2023.
  • Its Equity Ratio was 0.95 in Q3 2023, compared to 0.95 in Q2 2023 and 0.95 in Q1 2023.